HIV/AIDS epidemic

HIV/AIDS epidemic
Our world in data · CC BY 4.0 · source
Name	Human immunodeficiency virus / Acquired immunodeficiency syndrome
Synonyms	HIV, AIDS
Specialty	Infectious disease, Virology
Symptoms	Opportunistic infections, weight loss, fever, lymphadenopathy
Complications	Tuberculosis, Kaposi sarcoma, Pneumocystis pneumonia
Onset	Months to years after infection
Duration	Chronic
Causes	Human immunodeficiency virus
Risks	Unprotected sexual contact, contaminated syringes, vertical transmission, transfusion with contaminated blood
Prevention	Condom, pre-exposure prophylaxis, safe blood screening, needle-exchange programmes, antiretroviral prophylaxis
Medication	Antiretroviral therapy
Prognosis	Lifelong infection with effective suppression on therapy
Frequency	Tens of millions affected globally
Deaths	Millions since 1981

HIV/AIDS epidemic

The HIV/AIDS epidemic is the global pandemic caused by infection with Human immunodeficiency virus leading to Acquired immunodeficiency syndrome, first recognized in the early 1980s in United States clinical reports and rapidly identified in multiple regions including Central Africa, Haiti, and France. Early scientific, public health, and political responses involved collaborations among institutions such as the Centers for Disease Control and Prevention, the World Health Organization, and national ministries of health, while activism from groups like ACT UP and organizations such as the Joint United Nations Programme on HIV/AIDS shaped research, treatment access, and policy. Discoveries by researchers at laboratories associated with Institut Pasteur, Rockefeller University, and university centers in San Francisco and London established virology, diagnostics, and antiretroviral therapy milestones. The epidemic has provoked major international initiatives including the President's Emergency Plan for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

History

First clinical clusters were described in reports published by the Centers for Disease Control and Prevention in 1981 among patients in Los Angeles and New York City with opportunistic infections such as Pneumocystis pneumonia and Kaposi sarcoma. Retrospective serological and molecular analyses linked early cases to strains circulating in Central Africa and epidemiological work traced international spread via historical routes including labor migration, shipping, and travel involving locations like Kinshasa, Lisbon, and Port-au-Prince. In 1983–1984 competing research teams at Institut Pasteur and the National Cancer Institute identified the causative retrovirus and subsequent international validation by groups at Harvard University and University College London led to diagnostic assays licensed by biotechnology companies and regulatory agencies such as the Food and Drug Administration. The mid-1990s introduction of combination antiretroviral therapy, shaped by clinical trials conducted through networks including the International AIDS Society and the National Institutes of Health, transformed prognoses. Major policy landmarks included the establishment of UNAIDS and funding initiatives such as PEPFAR and the Global Fund.

Virology and Transmission

The etiologic agent, Human immunodeficiency virus types 1 and 2, is a retrovirus in the genus Lentivirus with key genes characterized by laboratories at institutions including Pasteur Institute and Scripps Research. Viral entry mechanisms involve envelope glycoproteins interacting with host receptors such as CD4 (T lymphocyte) and chemokine coreceptors discovered through molecular studies at Stanford University and the University of California, San Francisco. Transmission routes were elucidated through epidemiological investigations in cohorts studied by teams at Columbia University, Imperial College London, and public health agencies like the Public Health England: sexual contact, contaminated blood transfusion episodes prior to screening reforms, sharing of intravenous drug equipment, and vertical transmission during pregnancy, childbirth, or breastfeeding. Laboratory work on viral load and immune decline informed guidelines from organizations such as the World Health Organization and national programs in South Africa and Brazil for antiretroviral use to prevent mother-to-child transmission.

Epidemiology and Global Impact

Epidemiological surveillance coordinated by UNAIDS and the World Health Organization tracks prevalence and incidence across regions including Sub-Saharan Africa, Southeast Asia, Eastern Europe, and the Caribbean. Epicenters in countries like South Africa, Nigeria, and India have driven international funding and research priorities, while concentrated epidemics among key populations have been documented in cities such as Moscow, Bangkok, and San Francisco. Coinfections with Mycobacterium tuberculosis and hepatitis viruses shaped morbidity patterns analyzed by research consortia at Johns Hopkins University and the London School of Hygiene & Tropical Medicine. Global mortality and life-expectancy impacts prompted inclusion of HIV targets within the Millennium Development Goals and later the Sustainable Development Goals.

Prevention and Treatment

Prevention strategies encompass biomedical interventions like condom promotion, pre-exposure prophylaxis, male circumcision programs evaluated in trials in Uganda and South Africa, blood-screening systems reformed after transmission events, and harm-reduction services in venues coordinated with organizations such as Médecins Sans Frontières and WHO. Antiretroviral therapy regimens, including nucleoside reverse transcriptase inhibitors and protease inhibitors developed by pharmaceutical firms and trial networks, are delivered through national programs in Brazil, Rwanda, and Thailand and through international funding mechanisms such as PEPFAR and the Global Fund. Advances in diagnostics from companies and academic spin-offs enabled point-of-care testing in remote clinics in Mozambique and Peru, while vaccine research led by consortia including the HIV Vaccine Trials Network and institutions like Emory University continues alongside experimental modalities such as broadly neutralizing antibodies and gene-editing approaches under investigation at MIT and Cold Spring Harbor Laboratory.

Social, Economic, and Political Effects

The epidemic reshaped labor markets and demographic structures in nations including South Africa, Botswana, and Zambia, influencing policy in parliaments and legislatures such as the United States Congress and national assemblies across Sub-Saharan Africa. Health-system strengthening efforts tied to HIV programs affected service delivery in hospitals like Chris Hani Baragwanath Hospital and clinics supported by international partners such as the World Bank and Clinton Foundation. Trade and intellectual property debates involving World Trade Organization agreements and pharmaceutical companies influenced access to medicines, while major cultural responses appeared in works by artists and writers in cities such as New York City, London, and Johannesburg and in exhibitions at institutions like the Smithsonian Institution.

Stigma, Human Rights, and Advocacy

Stigma and discrimination against people living with HIV have prompted litigation and policy reform in courts and legislatures, including landmark cases adjudicated in South Africa and decisions influencing human-rights frameworks promoted by UNAIDS and Human Rights Watch. Grassroots advocacy by groups such as ACT UP, Treatment Action Campaign, and local NGOs in cities like Cape Town, Buenos Aires, and Kampala secured expanded testing, treatment access, and law reform addressing criminalization and confidentiality. International human-rights instruments and health diplomacy efforts involving the United Nations and bilateral programs have emphasized rights-based approaches to prevention, treatment, and social protection for marginalized populations including sex workers, prisoners, and people who use drugs.

Category:Infectious disease